Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Natco Pharma ties up with Gilead on hepatitis C drugs

Natco, a mid-sized player in India's crowded pharmaceutical industry, is the latest generic drugmaker to team up with Gilead on Sovaldi, having previously attempted to block the U.S. firm from getting a patent for the breakthrough drug in India in the hope of producing a cheaper version on its own. In September, Gilead announced similar licensing deals with seven other generic drugmakers.

Published
14 hours ago
From
Reuters
HCV Drugs Costly but Cure Might Not Be

Despite controversy over the cost of new hepatitis C (HCV) medications, they appear to be cheaper on a per-cure basis than earlier drugs, a researcher said here.

Published
14 hours ago
From
Manual Items
Gilead's Harvoni gains NICE yes - but won't face funding delay

Gilead's next generation hepatitis C pill Harvoni is set to be backed by NICE - and this time NHS England won't be delaying its funding as it has done with the firm's other hep C drug Sovaldi.

Published
03 March 2015
From
PM Live
Deferring hepatitis C treatment can lead to liver cancer and death, despite cure

People with HIV and hepatitis C co-infection who delay hepatitis C treatment remain at risk for liver failure, hepatocellular carcinoma and liver-related death even after being

Published
03 March 2015
By
Liz Highleyman
Progression to severe fibrosis or cirrhosis is common among baby boomers with hepatitis C in the US

The burden of hepatitis C virus (HCV) infection is high in the US, with a substantial number of individuals born between 1945 and 1965 having advanced liver

Published
03 March 2015
By
Liz Highleyman
Delay HCV Tx and Watch Patients Die

Delaying hepatitis C (HCV) treatment in patients who also have HIV increases the risk of liver complications and death even if the therapy is successful, a researcher said.

Published
02 March 2015
From
MedPage Today
Doctor Panel to Weigh Hepatitis C Drugs’ Costs in Guidelines

An influential advisory panel of doctors and health experts will for the first time address the cost-effectiveness of pricey hepatitis C drugs in updated guidelines that may change prescribing and coverage for the medicines.

Published
02 March 2015
From
Bloomberg
Two interferon-free regimens show high HCV cure rates for people with HIV and HCV co-infection

A pair of two-drug, 12-week regimens containing neither interferon nor ribavirin – sofosbuvir (Sovaldi) plus either ledipasvir (the Harvoni coformulation) or daclatasvir (Daklinza) – cured hepatitis

Published
27 February 2015
By
Liz Highleyman
NICE guidance recommends sofosbuvir (Sovaldi, Gilead Sciences) and simeprevir (Olysio, Janssen) for treating hepatitis C

Following a request from NHS England and consultation with stakeholders, the period during which NHS England has to comply with the recommendations for sofosbuvir is extended to 31 July 2015. The period during which NHS England has to comply with the recommendations for simeprevir has not been extended.

Published
26 February 2015
From
NICE press release
New hepatitis C treatments highly effective for HIV/HCV coinfected people

A pair of interferon-free combinations -- AbbVie's 3-drug Viekira Pak regimen and Gilead Science's sofosbuvir/ledipasvir (Harvoni) -- demonstrated good safety and cured more than 90% of genotype 1 HIV/HCV coinfected people, according to studies published in the February 23 advance edition of the Journal of the American Medical Association.

Published
26 February 2015
From
HIVandHepatitis.com
← First12345...159Next →

Filter by country